Aclaris Therapeutics (ACRS) Gross Margin (2017 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Gross Margin of 80.21% for Q1 2026, up 1499.0% year-over-year from 5.02% in Q1 2025, and up 36.14% quarter-over-quarter from 58.92% in Q4 2025.
Aclaris Therapeutics (ACRS) Gross Margin (2017 - 2026) Analysis & Trends
Aclaris Therapeutics' Gross Margin history runs 10 years deep, the most recent figure standing at 80.21% for Q1 2026.
- In Q1 2026, Gross Margin rose 1499.0% year-over-year to 80.21%; the TTM figure through Mar 2026 stood at 76.34% (down 966.0% YoY), while the FY2025 annual figure was 73.28%, down 1180.0% from the prior year.
- Gross Margin for Q1 2026 stood at 80.21%, up from 58.92% in the prior quarter.
- The five-year high for Gross Margin was 95.87% in Q4 2023, with the low at 20.51% in Q1 2022.
- The 5-year median for Gross Margin is 77.44% (2024), against an average of 71.38%.
- The sharpest annual moves came in 2022 and 2025: Gross Margin surged 6524 bps in 2022, then plunged 3343 bps in 2025.
- Aclaris Therapeutics' Gross Margin stood at 88.69% in 2022, then grew by 8 bps to 95.87% in 2023, then dropped by 4 bps to 92.35% in 2024, then slumped by 36 bps to 58.92% in 2025, then jumped by 36 bps to 80.21% in 2026.
- Business Quant data shows ACRS's Gross Margin at 80.21% in Q1 2026, 58.92% in Q4 2025, and 83.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 86.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.62% |
| Mar 31, 2026 | 80.21% |
| Dec 31, 2025 | 58.92% |
| Sep 30, 2025 | 83.69% |
| Jun 30, 2025 | 71.02% |
| Mar 31, 2025 | 65.22% |
| Dec 31, 2024 | 92.35% |
| Sep 30, 2024 | 84.95% |
| Jun 30, 2024 | 77.44% |
| Mar 31, 2024 | 66.26% |
| Dec 31, 2023 | 95.87% |
| Sep 30, 2023 | 90.86% |
| Jun 30, 2023 | 44.25% |
| Mar 31, 2023 | 68.04% |
| Dec 31, 2022 | 88.69% |
| Sep 30, 2022 | 95.15% |
| Jun 30, 2022 | 30.10% |
| Mar 31, 2022 | 20.51% |
| Dec 31, 2021 | 23.45% |
| Sep 30, 2021 | 33.76% |